Even if in clinical trials history of diabetes excludes the use of PI3K inhibitor, adverse events (mainly hyperglycemia) lead to treatment discontinuation is 20% of patients, despite closing monitoring (7). The gene discussed is PIK3CA; the disease is Hyperglycemia.